UNSPSC 51351622: Estradiol cypionate

This classification denotes a therapeutic estradiol, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E1DV054LO. European Medicines Agency schedules Estradiol cipionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01965MIG. Estradiol cypionate generally arises in the molecular formula C26H36O3. The term 'estradiol cypionate' is a U.S. Pharmacopeial Convention designation. Most nations, for tariff and trade purposes, schedule estradiol cypionate under HS 29372300.

As of Q4 2014, ESTRADIOL CYPIONATE remains US FDA's Preferred Term for this commodity. Estradiol cypionate bears US NLM identifiers UMLS ID C0059610 and NCI Concept Code C47991. SMILES: C[C@]12CC[C@@H]3C4CCC(CC4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC5CCCC5)O.

UNSPSC 51351622 Estradiol cypionate, a Commodity-level pharmaceutical product code, represents estradiol cypionate medications that state and local government health systems and public facilities procure through cooperative purchasing agreements and direct vendor contracts. The recent activity under this code centers on generic and branded pharmaceutical sourcing through multistate cooperative vehicles, where state health departments, local health authorities, and public facility networks establish master contracts with manufacturers and wholesalers to standardize pricing, ensure supply chain compliance, and manage inventory across participating jurisdictions. State and local issuing bodies soliciting under this code are primarily state health and human services departments, state pharmacy boards, and cooperative purchasing organizations that aggregate demand across multiple states and member agencies — including counties, cities, public hospitals, and correctional facilities that rely on these master agreements for routine pharmaceutical supply.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most visible recent opportunity — RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026. MMCAP's procurement spans participating state and local government facilities across multiple states including Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) and demonstrate cGMP compliance, DSCSA certification, and pricing flexibility across flat price, net price, and WAC-minus formats. The contract term is two years for new responders with optional extensions, effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing stability, and the remainder on administrative compliance and EDI capability. Vendors must maintain $5 million commercial general liability insurance, $2 million network security and privacy liability, and $2 million professional liability, with no set-aside designations named in the solicitation.